Print this page    •   Back to Web version of article

The Body Covers: The 8th International Congress on Drug Therapy in HIV Infection

Momentum for HLA-B*5701 Testing to Prevent Abacavir Hypersensitivity Grows

Coverage provided by Graeme Moyle, M.D.

November 16, 2006

Abacavir (ABC, Ziagen) is a convenient nucleoside reverse transcriptase inhibitor with an excellent long-term tolerability profile. Of course, it has one key drawback: a systemic hypersensitivity reaction. Abacavir hypersensitivity reactions typically occur in the first six weeks of therapy and consist of a range of signs and symptoms that are also common to viral infections, making the diagnosis a clinical challenge. The event is typically diagnosed in 5% to 9% of persons who receive abacavir; the rates vary depending on population characteristics, particularly ethnicity. For example, people of black African decent have lower rates of hypersensitivity reaction.

Retrospective, case-control studies identified the HLA-B*5701 allele, together with some linked alleles, to be closely associated with abacavir hypersensitivity reactions,1,2 and a molecular mechanism for this association has been described. These studies suggested that testing for the presence of HLA-B*5701 may have a negative predictive value greater than 94%. Thus, preventing HLA-B*5701-positive persons from receiving abacavir has the potential to dramatically reduce the rate of hypersensitivity events seen in clinical practice. Several cohort studies have now been reported and suggest that prospective use of HLA-B*5701 testing can have a significant impact on the hypersensitivity event rate observed with abacavir use.3,4

Prospective use of the HLA-B*5701 test was introduced in the Chelsea and Westminster Hospital in London in August 2005. The experience of the first 11 months of this program was compared with a retrospective case review of all individuals commencing abacavir in the year prior to HLA-B*5701 testing.5

Over the first 11 months of testing, 739 tests were performed with only four test failures. A total of 54 individuals (7.3%) were HLA-B*5701 positive, with similar rates observed in men and women (6.9% and 9.9%, respectively; P = .35). Positive tests were reported in both white (7.6%) and black (9.0%) individuals; however, these rates may have been overestimated due to methodological issues with the test.

Two treatment-naive individuals who tested positive for HLA-B*5701 commenced abacavir therapy, and both subsequently developed hypersensitivity reactions. In contrast, 47 treatment-naive individuals negative for HLA-B*5701 commenced abacavir therapy, and none discontinued treatment.

An additional 151 treatment-experienced individuals without HLA-B*5701 switched to abacavir-containing therapy, and eight (5.3%) discontinued abacavir during the first three months of treatment, four (2.6%) due to suspected abacavir hypersensitivity reaction. The signs and symptoms experienced by these individuals -- typically fever with other systemic symptoms -- were consistent with abacavir hypersensitivity reaction. Two of the four patients agreed to skin patch testing, with one individual demonstrating a positive reaction. Further investigation of this individual is ongoing.

In the year prior to HLA-B*5701 testing, 10 out of 134 individuals (7.5%) discontinued abacavir use due to a possible hypersensitivity reaction. After the introduction of prospective HLA-B*5701 testing, the event rate dropped to 2.0%, a statistically significant reduction in the event rate (P = .03).

These and other prospective cohort data support the use of HLA-B*5701 testing to reduce the relative risk of abacavir hypersensitivity reaction in clinical practice. However, several cases reported here suggest that continued vigilance for hypersensitivity reaction is required even when abacavir is used in individuals without this genetic marker. A large, prospective study of this test is now underway, and data on more than 1,400 persons commencing abacavir are likely to be reported at the 4th International AIDS Society Conference on HIV Pathogenesis and Treatment, in Sydney, Australia, in July 2007.

Footnotes

  1. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. March 30, 2002;359(9312):1121-1122.

  2. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. March 2, 2002;359(9308):727-732.

  3. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis. July 1, 2006;43(1):99-102.

  4. Reeves I, Fisher M, Churchill D. Clinical utility of HLA-B*5701 testing in a UK clinic cohort. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo. Abstract 667a.

  5. Waters L, Gritz A, Maitland D, Nelson M. HLA-B5701 testing and abacavir hypersensitivity: a single centre experience. In: Program and abstracts of the 8th International Congress on Drug Therapy in HIV Infection; November 12-16, 2006; Glasgow, United Kingdom. Abstract PL9.2.
    View slides: Download PowerPoint


Copyright Body Health Resources Corporation. All rights reserved.

You can find this article online by typing the following address into your Web browser:
http://www.thebody.com/content/art38814.html

Please Note: Knowledge about HIV changes rapidly. Note the date of this article's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this article.

General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your healthcare provider.